Followers | 18 |
Posts | 2062 |
Boards Moderated | 0 |
Alias Born | 12/13/2009 |

Sunday, May 18, 2025 3:49:39 PM
Debate demands lucid argument.
In this case, it also requires some basic understanding of options and math skills. All your word salad responses in this thread don't change the fact that you tried to make the argument that outstanding January AVXL options contracts constitute a hedge against "a good portion" of the short position. As Wolf was quick to point out, the entire January open interest in call options covers less than10% of the shorted shares. Consider taking being called out like a man and quit trying to change the subject of the thread because there is no way for you to salvage your original post.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2025 09:25:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2025 09:30:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/09/2025 09:30:47 PM
- Anavex Life Sciences to Participate at Upcoming Healthcare Conferences • GlobeNewswire Inc. • 05/14/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2025 08:31:17 PM
- Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/13/2025 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 • GlobeNewswire Inc. • 05/06/2025 11:30:00 AM
- Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 05/01/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2025 12:00:38 AM
- Anavex Life Sciences to Participate in The Citizens Life Sciences Conference • GlobeNewswire Inc. • 04/30/2025 11:30:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/25/2025 08:40:36 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/25/2025 08:35:45 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/25/2025 08:31:01 PM
- Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board • GlobeNewswire Inc. • 04/23/2025 11:30:00 AM
- Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East • GlobeNewswire Inc. • 04/21/2025 11:30:00 AM
- Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease • GlobeNewswire Inc. • 04/05/2025 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:46:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:46:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:45:40 AM
- Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2025 11:30:00 AM
- Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/24/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2025 02:06:26 PM
- Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/12/2025 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 • GlobeNewswire Inc. • 02/05/2025 12:30:00 PM
- Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio • GlobeNewswire Inc. • 01/27/2025 12:30:00 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM